A newly-discovered pathway known as Transient Receptor Potential Mleastatin 3 (TRPM3) could provide more treatment options for kidney cancer, according to research published in Cancer Cell.
Researchers from the Cincinnati Cancer center led by Maria Czyzyk-Krzeska, MD, PhD, analyzed the expression of the TRPM3 pathway through animal models, human cell cultures and tumor specimens in order to study its effect on tumor growth.
“TRPM3 is increased in 60% of kidney clear cell carcinomas where it promotes growth of tumors by stimulating intracellular pathways that initiate autophagy,” Dr. Czyzyk-Krzeska said. “During tumor growth, cancer cells become addicted to autophagy as a source of nutrients.”
The TRPM3 pathway, however, helps to regulate kidney cancer cell autophagy, and targeting it therapeutically could lead to more treatment options.
The researchers believe that identification of the pathway can lead to actionable targets in kidney cancer, noting that there are already TRPM3 inhibitors on the market that are approved by the FDA.
Cincinnati Cancer Center (CCC) researchers have discovered that a membrane channel, Transient Receptor Potential Melastatin 3, or TRPM3, promotes growth of kidney cancer tumors, and targeting this channel therapeutically could lead to more treatments for a disease that currently has few treatment options.
A membrane channel is a family of proteins that allows the movement of ions, water or other solutions to pass through the membrane. These findings are being published in the Nov. 10, 2014, edition of the journal Cancer Cell.